AGIOS PHARMACEUTICALS INC (AGIO) Stock Analyst Ratings
USA - NASDAQ:AGIO - US00847X1046 - Common Stock
43.24 USD
+0.06 (+0.14%)
43.24 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 79% to AGIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 49.57. This target is 14.64% above the current price.
AGIO was analyzed by 14 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about AGIO.
In the previous month the buy percentage consensus was at a similar level.
AGIO was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-28 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-05-02 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-02-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-09 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-11-01 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-11-01 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-10-16 | ScotiaBank | Initiate | Sector Outperform |
| 2024-10-10 | Raymond James | Reiterate | Outperform |
| 2024-09-27 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-09-19 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-06-17 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-06-13 | JP Morgan | Reiterate | Neutral -> Neutral |
| 2024-06-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-06-04 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-05-03 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-04-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-02-23 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-02-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-11-03 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-08-07 | JP Morgan | Maintains | Neutral -> Neutral |
| 2023-06-27 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-02-03 | Piper Sandler | Initiate | Overweight |
| 2022-12-01 | JP Morgan | Maintains | Neutral |
| 2022-11-17 | Goldman Sachs | Upgrade | Sell -> Neutral |
AGIOS PHARMACEUTICALS INC / AGIO FAQ
What is the price target for AGIO stock?
14 analysts have analysed AGIO and the average price target is 49.57 USD. This implies a price increase of 14.64% is expected in the next year compared to the current price of 43.24.
Can you provide the consensus rating for AGIOS PHARMACEUTICALS INC stock?
The consensus rating for AGIOS PHARMACEUTICALS INC (AGIO) is 78.5714 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed AGIOS PHARMACEUTICALS INC (AGIO)?
The number of analysts covering AGIOS PHARMACEUTICALS INC (AGIO) is 14.